Wednesday, June 10, 2020 11:44:33 AM
According to the U.S. Food and Drug Administration (FDA), expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Recent BCRX News
- BioCryst Launches ORLADEYO® (berotralstat) in Ireland • GlobeNewswire Inc. • 11/18/2024 07:00:09 AM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 11/06/2024 12:00:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2024 10:19:10 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/05/2024 12:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 12:06:59 PM
- BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) • GlobeNewswire Inc. • 10/24/2024 12:00:00 PM
- BioCryst to Report Third Quarter 2024 Financial Results on November 4 • GlobeNewswire Inc. • 10/21/2024 11:00:23 AM
- BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) • GlobeNewswire Inc. • 10/14/2024 11:00:00 AM
- BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/03/2024 11:00:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 11:06:38 AM
- BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome • GlobeNewswire Inc. • 10/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 11:11:26 AM
- U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile • GlobeNewswire Inc. • 09/30/2024 11:00:00 AM
- BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/10/2024 04:09:00 PM
- BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium • GlobeNewswire Inc. • 09/06/2024 06:00:11 AM
- BioCryst Appoints Dr. Donald Fong Chief Medical Officer • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/04/2024 11:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:17:53 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 08/22/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 08:38:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:05:05 AM
- BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/05/2024 11:00:24 AM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM